首页> 外文期刊>Trials >Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial
【24h】

Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial

机译:术后静脉内施用蔗糖铁与术后口服铁治疗小儿腹部成形术性贫血(ISAPA):一项随机对照试验的研究方案

获取原文
           

摘要

Background Anaemia and iron deficiency are common complications following post-bariatric abdominoplasty. Given the low oral absorbability of iron resulting from bariatric surgery, it has been hypothesised that postoperative intravenously administered iron supplementation could be used to treat anaemia and to prevent the development of iron deficiency in these patients. Methods/Design In this multicentre open-label randomised clinical trial, 56 adult women undergoing post-bariatric anchor-line abdominoplasty will be allocated at a ratio of 1:1 for postoperative supplementation with two intravenously administered applications of 200?mg of iron saccharate or postoperative supplementation with 100?mg of iron polymaltose complex administered orally, twice a day for 8?weeks. The primary outcome is the difference in mean haemoglobin levels between the two groups at eight postoperative weeks. Secondary outcomes evaluated at one, four and eight postoperative weeks include iron profile, reticulocyte count, overall quality of life measured using the Short-Form 36 Health Survey (SF-36) questionnaire, fatigue measured using the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), adverse effects and postoperative complications. Discussion This randomised clinical trial aims to evaluate the haematopoietic effectiveness of intravenously administered iron supplementation in patients undergoing post-bariatric abdominoplasty. A more effective recovery of haemoglobin levels could help improve the patients’ quality of life and could provide an improved haematological status in preparation for the subsequent and frequent plastic surgeries these patients undergo. Trial registration Clinicaltrials.gov Identifier: NCT01857011 (8 May 2013), Universal Trial Number U111-1169-6223, Brazilian Clinical Trials Registry (REBEC): RBR-2JGRKQ .
机译:背景贫血和铁缺乏症是重症后腹部整形术后的常见并发症。鉴于减肥手术引起的铁口服吸收能力低,据推测,术后静脉注射铁补充剂可用于治疗贫血和预防这些患者的铁缺乏症。方法/设计在这项多中心,开放标签的随机临床试验中,将对比例为56的接受aria门后锚行腹部成形术的成年女性按1:1的比例进行分配,以补充200 mg糖精铁或术后补充口服100mg的多麦芽糖铁复合物,每天两次,连续8周。主要结局是术后八周两组之间平均血红蛋白水平的差异。术后一,四,八周评估的次要结局包括铁谱,网织红细胞计数,使用36型短期健康调查(SF-36)问卷测量的整体生活质量,使用慢性病治疗功能评估-疲劳测量的疲劳(FACIT-F),不良反应和术后并发症。讨论该随机临床试验旨在评估静脉注射铁补充剂在接受aria门腹部成形术的患者中的造血效力。血红蛋白水平的更有效恢复可以帮助改善患者的生活质量,并可以改善血液学状况,为这些患者随后进行的频繁的整容手术做准备。试验注册Clinicaltrials.gov标识符:NCT01857011(2013年5月8日),通用试验编号U111-1169-6223,巴西临床试验注册中心(REBEC):RBR-2JGRKQ。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号